Viagra-class Alzheimer's pill reports a benefit in one trial subgroup
AriBio, a South Korean company, has reported topline results from a phase three trial of AR1001, an oral once-daily tablet for early Alzheimer's disease. The trial ran across 13 countries, including the UK, for about one year. The company says decline slowed by 31% in 604 patients who took no other Alzheimer's drugs. Results were presented at the Clinical Trials on Alzheimer's Disease conference in Boston.
AR1001 belongs to the phosphodiesterase-5 inhibitor class, the same as Viagra, but it is being developed specifically for Alzheimer's. It relaxes blood vessels and raises blood flow to the brain. Reported side-effects were mostly mild to moderate.
Why it matters for abundance: dementia is forecast to affect 153 million people worldwide by 2050, and Alzheimer's is the most common form. A tablet taken once a day would be far easier to deliver than a treatment that needs clinic visits, which would help both patients and the people who care for them. No price has been reported, so it is not yet known whether this would be cheap.
The caveats are large. These are company figures, not yet peer-reviewed or assessed by regulators. In the wider group, which included patients on other Alzheimer's drugs, the result was not statistically significant. Experts not involved called the data very promising and very encouraging, but urged caution and said the mixed result needs investigating. They called for further trials and regulatory scrutiny before AR1001 could be prescribed. The Alzheimer's Society says people should not take Viagra to try to treat Alzheimer's.
Source: Guardian
Many Minded